<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996801</url>
  </required_header>
  <id_info>
    <org_study_id>5442-012</org_study_id>
    <secondary_id>2009-014729-18</secondary_id>
    <secondary_id>CTRI/2010/091/000258</secondary_id>
    <nct_id>NCT00996801</nct_id>
  </id_info>
  <brief_title>MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)</brief_title>
  <official_title>A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to demonstrate that additional gain in bone mineral density (BMD) can be
      achieved by switching to MK-5442 from an oral bisphosphonate in participants who have been
      receiving oral bisphosphonate therapy for at least 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was originally planned for a duration of 2 years and included efficacy analysis of
      a 15 mg MK-5442 treatment arm. Amendment 1 of the protocol eliminated the 2nd year of the
      study as well the 15-mg arm. Enrollment into the 15-mg MK-5442 arm was stopped as a result of
      the amendment and all participants who had been randomly assigned to the MK-5442 15-mg
      treatment arm were discontinued from the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Areal bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DXA) scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Trough Serum Calcium Level Exceeding Predefined Limits At Least Once</measure>
    <time_frame>Baseline through Month 12</time_frame>
    <description>Normal serum calcium level is 8-10 mg/dL (2-2.5 mmol/L) with some interlaboratory variation in the reference range, and hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL (&gt;2.5 mmol/L).
Based on these references, ≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with at least a one calcium level value ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; adverse event (AE). A Tier 1 AE was an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Trough Albumin-Corrected Calcium Level Exceeding Predefined Limits At Least Once</measure>
    <time_frame>Baseline through Month 12</time_frame>
    <description>Albumin-Corrected Calcium = ([4 - plasma albumin in g/dL] × 0.8 + serum calcium).
≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with at least one albumin-corrected calcium level value ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; AE (an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Predefined Tier 1 Adverse Events</measure>
    <time_frame>Baseline through Month 12</time_frame>
    <description>Osteonecrosis of the jaw (ONJ), kidney stones, and bone neoplasms were predefined Tier-1 AEs in the study (an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Total Hip Areal BMD</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Femoral Neck Areal BMD</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Trochanter Areal BMD</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Total Body Areal BMD</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in 1/3 Distal Forearm Areal BMD</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD (vBMD) of the Lumbar Spine</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>vBMD was measured using quantitative computed tomography (QCT) in order to assess bone strength. Quantitative computed tomography is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD of the Hip</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Lumbar Spine</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Hip</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Urinary-N Telopeptides of Type 1 Collagen (u-NTx)</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Urinary, type I collagen, crosslinked N-telopeptide (uNTx) is a biomarker used to measure the rate of bone turnover found in urine.
uNTx was expressed in units of nanomoles (nM) per bone collagen equivalents (BCE) per millimoles of creatinine (Cr) or nM/BCE/mM Cr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Serum C-Terminal Propeptide of Type 1 Collagen (s-CTx)</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>C-Terminal Telopeptide Collagen I is used as a serum-marker of bone resorption in the assessment of osteoporosis and in measured in units of nanograms (n)/milliliter (ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Serum N-Terminal Propeptide (s-P1NP)</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>s-P1NP is a sensitive marker of bone formation rate in the assessment of osteoporosis and is measured in units of ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP)</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Bone Specific Alkaline Phosphatase is a biomarker of bone formation and is measured in units of μg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Percent Change From Baseline to Month 12 in Serum Osteocalcin</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Serum osteocalcin is a biomarker of bone formation and is measured using units of nanograms (ng) / milliliter
(mL).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">526</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5442</intervention_name>
    <description>MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months</description>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-5442</intervention_name>
    <description>Matching placebo to MK-5442 taken orally, once-daily, for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate Sodium</intervention_name>
    <description>Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months</description>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <other_name>FOSAMAX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Alendronate</intervention_name>
    <description>Placebo to alendronate once-weekly for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Taking oral bisphosphonate treatment for osteoporosis for at least 3 of the past 4
             years. At present, and for the past 12 months, treated with alendronate

          -  Bone Mineral Density (BMD) T-score that is ≤ -1.5 at one or more of the following
             anatomic sites; lumbar spine, femoral neck, trochanter, and total hip, AND a BMD
             T-score at all of these sites that is ≥ -4.0, AND a history of at least one fragility
             fracture, OR, a BMD T-score that is ≤ -2.5 at one or more of the following anatomic
             sites; lumbar spine, femoral neck, trochanter, and total hip, AND a BMD T-score at all
             of these sites that is ≥ -4.0

          -  Postmenopausal for at least 5 years

        Exclusion Criteria:

          -  Obesity (ie, weight greater than 250 pounds) that prohibits the use of dual-emission
             X-ray absorptiometry (DXA)

          -  Received intravenous (IV) bisphosphonates, fluoride treatment at a dose &gt;1 mg/day for
             more than 2 weeks, strontium, growth hormone, a cathepsin K (CTSK) inhibitor, or a
             receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor at any time in
             the past

          -  Use of oral bisphosphonates other than alendronate in the last 12 months, parathyroid
             hormone (PTH) in the last 24 months, cyclosporin for more than 2 weeks in the last 6
             months, heparin in the last 2 weeks, or anabolic steroids or glucocorticoids for more
             than 2 weeks in the past 6 months

          -  Use of estrogen with or without progestin or a selective estrogen receptor modulator
             (SERM) in the last 6 months or calcitonin in the last 30 days

          -  Has used pioglitazone hydrochloride or rosiglitazone hydrochloride in the last 6
             months

          -  Taking more than 10,000 International Units (IU) vitamin A daily or more than 5,000 IU
             vitamin D daily

          -  Has had a total thyroidectomy

          -  History of Paget's disease

          -  Has human immunodeficiency virus (HIV)

          -  History of cancer in the last 5 years, except certain skin or cervical cancers

          -  History of major upper gastrointestinal (GI) mucosal erosive disease

          -  Unable to adhere to dosing instructions for alendronate in regard to fasting and
             positioning

          -  Not ambulatory
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP 2nd, Rosenberg E, Denker AE. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporos Int. 2016 Jan;27(1):377-86. doi: 10.1007/s00198-015-3392-7. Epub 2015 Nov 10.</citation>
    <PMID>26556736</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <results_first_submitted>August 31, 2012</results_first_submitted>
  <results_first_submitted_qc>October 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2012</results_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="P2">
          <title>MK-5442 5 mg</title>
          <description>Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="P3">
          <title>MK-5442 7.5 mg</title>
          <description>Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="P4">
          <title>MK-5442 10 mg</title>
          <description>Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="P5">
          <title>MK-5442 15 mg</title>
          <description>Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="P6">
          <title>Alendronate 70 mg</title>
          <description>Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="87"/>
                <participants group_id="P5" count="88">15-mg arm was discontinued as a result of Protocol Amendment 1.</participants>
                <participants group_id="P6" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="88"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="B2">
          <title>MK-5442 5 mg</title>
          <description>Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="B3">
          <title>MK-5442 7.5 mg</title>
          <description>Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="B4">
          <title>MK-5442 10 mg</title>
          <description>Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="B5">
          <title>MK-5442 15 mg</title>
          <description>Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="B6">
          <title>Alendronate 70 mg</title>
          <description>Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="88"/>
            <count group_id="B4" value="87"/>
            <count group_id="B5" value="88"/>
            <count group_id="B6" value="87"/>
            <count group_id="B7" value="526"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="7.8"/>
                    <measurement group_id="B2" value="66.5" spread="8.8"/>
                    <measurement group_id="B3" value="67.3" spread="7.1"/>
                    <measurement group_id="B4" value="68.2" spread="6.9"/>
                    <measurement group_id="B5" value="68.1" spread="7.4"/>
                    <measurement group_id="B6" value="66.9" spread="7.5"/>
                    <measurement group_id="B7" value="67.5" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="88"/>
                    <measurement group_id="B6" value="87"/>
                    <measurement group_id="B7" value="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD)</title>
        <description>Areal bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DXA) scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD)</title>
          <description>Areal bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DXA) scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
          <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" lower_limit="-1.37" upper_limit="0.66"/>
                    <measurement group_id="O2" value="-0.67" lower_limit="-1.67" upper_limit="0.33"/>
                    <measurement group_id="O3" value="-0.52" lower_limit="-1.56" upper_limit="0.52"/>
                    <measurement group_id="O4" value="-0.53" lower_limit="-1.61" upper_limit="0.56"/>
                    <measurement group_id="O5" value="1.29" lower_limit="0.25" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.58</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.37</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.23</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Total Hip Areal BMD</title>
        <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Total Hip Areal BMD</title>
          <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
          <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" lower_limit="-2.24" upper_limit="-0.65"/>
                    <measurement group_id="O2" value="-2.18" lower_limit="-2.97" upper_limit="-1.39"/>
                    <measurement group_id="O3" value="-2.16" lower_limit="-2.98" upper_limit="-1.33"/>
                    <measurement group_id="O4" value="-1.66" lower_limit="-2.52" upper_limit="-0.80"/>
                    <measurement group_id="O5" value="0.46" lower_limit="-0.36" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-2.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.90</ci_lower_limit>
            <ci_upper_limit>-1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.83</ci_lower_limit>
            <ci_upper_limit>-1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-2.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.22</ci_lower_limit>
            <ci_upper_limit>-1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.99</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.93</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.699</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Femoral Neck Areal BMD</title>
        <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Femoral Neck Areal BMD</title>
          <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
          <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" lower_limit="-2.15" upper_limit="-0.36"/>
                    <measurement group_id="O2" value="-2.12" lower_limit="-3.00" upper_limit="-1.23"/>
                    <measurement group_id="O3" value="-1.37" lower_limit="-2.29" upper_limit="-0.44"/>
                    <measurement group_id="O4" value="-1.84" lower_limit="-2.80" upper_limit="-0.88"/>
                    <measurement group_id="O5" value="-0.08" lower_limit="-1.01" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.43</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.14</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.335</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.26</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.857</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.542</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.96</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Trochanter Areal BMD</title>
        <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Trochanter Areal BMD</title>
          <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
          <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-1.35" upper_limit="0.76"/>
                    <measurement group_id="O2" value="-1.56" lower_limit="-2.60" upper_limit="-0.52"/>
                    <measurement group_id="O3" value="-1.50" lower_limit="-2.59" upper_limit="-0.41"/>
                    <measurement group_id="O4" value="-1.52" lower_limit="-2.66" upper_limit="-0.38"/>
                    <measurement group_id="O5" value="1.68" lower_limit="0.59" upper_limit="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.91</ci_lower_limit>
            <ci_upper_limit>-1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-3.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>-1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-3.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.66</ci_lower_limit>
            <ci_upper_limit>-1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.180</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.93</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.180</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.81</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.180</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.68</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Total Body Areal BMD</title>
        <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Total Body Areal BMD</title>
          <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
          <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-0.83" upper_limit="0.49"/>
                    <measurement group_id="O2" value="-0.54" lower_limit="-1.18" upper_limit="0.10"/>
                    <measurement group_id="O3" value="-0.69" lower_limit="-1.37" upper_limit="-0.01"/>
                    <measurement group_id="O4" value="-1.10" lower_limit="-1.77" upper_limit="-0.44"/>
                    <measurement group_id="O5" value="0.82" lower_limit="0.15" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.46</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.93</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.383</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.383</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.96</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in 1/3 Distal Forearm Areal BMD</title>
        <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in 1/3 Distal Forearm Areal BMD</title>
          <description>Areal bone mineral density (BMD) was measured using DXA scanning technology. Scanning is performed with two X-ray beams with different energy levels which are aimed at the participant's bones. When soft tissue absorption is subtracted out, the BMD is determined from the absorption of each beam by bone.
BMD = BMC / W, where BMD = bone mineral density in g/cm^2, BMC = bone mineral content in g/cm, and W = width at the scanned line in cm</description>
          <population>Full Analysis Set (FAS): participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" lower_limit="-1.54" upper_limit="0.46"/>
                    <measurement group_id="O2" value="-1.38" lower_limit="-2.36" upper_limit="-0.40"/>
                    <measurement group_id="O3" value="-0.92" lower_limit="-1.95" upper_limit="0.12"/>
                    <measurement group_id="O4" value="-2.01" lower_limit="-3.05" upper_limit="-0.98"/>
                    <measurement group_id="O5" value="-0.91" lower_limit="-1.92" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.680</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.88</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.993</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.230</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.67</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.333</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.29</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.577</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.07</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD (vBMD) of the Lumbar Spine</title>
        <description>vBMD was measured using quantitative computed tomography (QCT) in order to assess bone strength. Quantitative computed tomography is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS), QCT Subset: QCT was performed on a subset of the FAS (participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data).
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD (vBMD) of the Lumbar Spine</title>
          <description>vBMD was measured using quantitative computed tomography (QCT) in order to assess bone strength. Quantitative computed tomography is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
          <population>Full Analysis Set (FAS), QCT Subset: QCT was performed on a subset of the FAS (participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data).
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="-1.22" upper_limit="1.57"/>
                    <measurement group_id="O2" value="-0.25" lower_limit="-1.55" upper_limit="1.05"/>
                    <measurement group_id="O3" value="0.08" lower_limit="-1.29" upper_limit="1.44"/>
                    <measurement group_id="O4" value="0.16" lower_limit="-1.28" upper_limit="1.61"/>
                    <measurement group_id="O5" value="1.74" lower_limit="0.21" upper_limit="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.22</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.82</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.53</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.937</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.61</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.992</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.21</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.992</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.93</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD of the Hip</title>
        <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS), QCT Subset: QCT was performed on a subset of the FAS (participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data).
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD of the Hip</title>
          <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
          <population>Full Analysis Set (FAS), QCT Subset: QCT was performed on a subset of the FAS (participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data).
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-1.41" upper_limit="1.36"/>
                    <measurement group_id="O2" value="0.76" lower_limit="-0.53" upper_limit="2.05"/>
                    <measurement group_id="O3" value="0.81" lower_limit="-0.57" upper_limit="2.18"/>
                    <measurement group_id="O4" value="0.27" lower_limit="-1.16" upper_limit="1.71"/>
                    <measurement group_id="O5" value="1.23" lower_limit="-0.23" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.824</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.50</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.824</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.28</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.624</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.23</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.700</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.700</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.759</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.60</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Lumbar Spine</title>
        <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS), QCT Subset: QCT was performed on a subset of the FAS (participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data).
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Lumbar Spine</title>
          <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
          <population>Full Analysis Set (FAS), QCT Subset: QCT was performed on a subset of the FAS (participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data).
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" lower_limit="-15.01" upper_limit="13.66"/>
                    <measurement group_id="O2" value="-3.41" lower_limit="-16.35" upper_limit="9.52"/>
                    <measurement group_id="O3" value="14.66" lower_limit="0.91" upper_limit="28.41"/>
                    <measurement group_id="O4" value="-0.34" lower_limit="-14.49" upper_limit="13.82"/>
                    <measurement group_id="O5" value="12.80" lower_limit="-2.31" upper_limit="27.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-16.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.15</ci_lower_limit>
            <ci_upper_limit>6.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.853</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>1.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.90</ci_lower_limit>
            <ci_upper_limit>21.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.327</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-13.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.67</ci_lower_limit>
            <ci_upper_limit>9.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.940</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.91</ci_lower_limit>
            <ci_upper_limit>18.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>15.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.86</ci_lower_limit>
            <ci_upper_limit>38.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.973</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.23</ci_lower_limit>
            <ci_upper_limit>19.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Hip</title>
        <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Full Analysis Set (FAS), QCT Subset: QCT was performed on a subset of the FAS (participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data).
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcomes analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Hip</title>
          <description>vBMD was measured using QCT in order to assess bone strength. QCT is a three-dimensional non-projectional technique that quantifies trabecular and cortical BMD in the lumbar spine and hip as a true volumetric mineral density in g/cm^3.</description>
          <population>Full Analysis Set (FAS), QCT Subset: QCT was performed on a subset of the FAS (participants who received at least one dose of study treatment, had at least one post-randomization observation, and who had baseline data).
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcomes analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-0.67" upper_limit="0.86"/>
                    <measurement group_id="O2" value="-0.49" lower_limit="-1.19" upper_limit="0.22"/>
                    <measurement group_id="O3" value="-0.15" lower_limit="-0.90" upper_limit="0.60"/>
                    <measurement group_id="O4" value="-0.16" lower_limit="-0.94" upper_limit="0.62"/>
                    <measurement group_id="O5" value="0.99" lower_limit="0.19" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.29</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.19</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.509</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.843</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.843</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.43</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Urinary-N Telopeptides of Type 1 Collagen (u-NTx)</title>
        <description>Urinary, type I collagen, crosslinked N-telopeptide (uNTx) is a biomarker used to measure the rate of bone turnover found in urine.
uNTx was expressed in units of nanomoles (nM) per bone collagen equivalents (BCE) per millimoles of creatinine (Cr) or nM/BCE/mM Cr</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Per Protocol Population: defined as the subset of the APaT population that excluded participants based on critical protocol violations.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Urinary-N Telopeptides of Type 1 Collagen (u-NTx)</title>
          <description>Urinary, type I collagen, crosslinked N-telopeptide (uNTx) is a biomarker used to measure the rate of bone turnover found in urine.
uNTx was expressed in units of nanomoles (nM) per bone collagen equivalents (BCE) per millimoles of creatinine (Cr) or nM/BCE/mM Cr</description>
          <population>Per Protocol Population: defined as the subset of the APaT population that excluded participants based on critical protocol violations.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.64" lower_limit="47.71" upper_limit="81.29"/>
                    <measurement group_id="O2" value="86.51" lower_limit="68.86" upper_limit="106.01"/>
                    <measurement group_id="O3" value="83.32" lower_limit="64.49" upper_limit="102.08"/>
                    <measurement group_id="O4" value="107.44" lower_limit="86.65" upper_limit="130.54"/>
                    <measurement group_id="O5" value="0.18" lower_limit="-9.45" upper_limit="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>86.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64.87</ci_lower_limit>
            <ci_upper_limit>108.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>82.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63.00</ci_lower_limit>
            <ci_upper_limit>101.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>107.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.03</ci_lower_limit>
            <ci_upper_limit>133.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.104</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>22.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>49.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>18.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.11</ci_lower_limit>
            <ci_upper_limit>42.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>43.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.85</ci_lower_limit>
            <ci_upper_limit>75.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Serum C-Terminal Propeptide of Type 1 Collagen (s-CTx)</title>
        <description>C-Terminal Telopeptide Collagen I is used as a serum-marker of bone resorption in the assessment of osteoporosis and in measured in units of nanograms (n)/milliliter (ml).</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Per Protocol Population: defined as the subset of the APaT population that excluded participants based on critical protocol violations.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Serum C-Terminal Propeptide of Type 1 Collagen (s-CTx)</title>
          <description>C-Terminal Telopeptide Collagen I is used as a serum-marker of bone resorption in the assessment of osteoporosis and in measured in units of nanograms (n)/milliliter (ml).</description>
          <population>Per Protocol Population: defined as the subset of the APaT population that excluded participants based on critical protocol violations.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.80" lower_limit="131.23" upper_limit="205.54"/>
                    <measurement group_id="O2" value="214.09" lower_limit="173.92" upper_limit="260.15"/>
                    <measurement group_id="O3" value="227.07" lower_limit="184.11" upper_limit="276.53"/>
                    <measurement group_id="O4" value="251.08" lower_limit="204.31" upper_limit="305.04"/>
                    <measurement group_id="O5" value="26.78" lower_limit="10.58" upper_limit="45.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>187.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>154.44</ci_lower_limit>
            <ci_upper_limit>221.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>200.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>161.21</ci_lower_limit>
            <ci_upper_limit>240.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>224.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>180.19</ci_lower_limit>
            <ci_upper_limit>270.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>48.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.75</ci_lower_limit>
            <ci_upper_limit>93.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>61.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.80</ci_lower_limit>
            <ci_upper_limit>114.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>85.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.70</ci_lower_limit>
            <ci_upper_limit>144.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Serum N-Terminal Propeptide (s-P1NP)</title>
        <description>s-P1NP is a sensitive marker of bone formation rate in the assessment of osteoporosis and is measured in units of ng/ml.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Per Protocol Population: defined as the subset of the APaT population that excluded participants based on critical protocol violations.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Serum N-Terminal Propeptide (s-P1NP)</title>
          <description>s-P1NP is a sensitive marker of bone formation rate in the assessment of osteoporosis and is measured in units of ng/ml.</description>
          <population>Per Protocol Population: defined as the subset of the APaT population that excluded participants based on critical protocol violations.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.61" lower_limit="51.82" upper_limit="87.27"/>
                    <measurement group_id="O2" value="127.18" lower_limit="105.07" upper_limit="151.68"/>
                    <measurement group_id="O3" value="125.69" lower_limit="102.92" upper_limit="151.01"/>
                    <measurement group_id="O4" value="163.96" lower_limit="136.79" upper_limit="194.24"/>
                    <measurement group_id="O5" value="-5.85" lower_limit="-14.99" upper_limit="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>133.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>110.01</ci_lower_limit>
            <ci_upper_limit>156.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>133.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>110.01</ci_lower_limit>
            <ci_upper_limit>156.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>131.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>110.70</ci_lower_limit>
            <ci_upper_limit>152.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>169.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>141.59</ci_lower_limit>
            <ci_upper_limit>199.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>58.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.42</ci_lower_limit>
            <ci_upper_limit>88.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>57.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.76</ci_lower_limit>
            <ci_upper_limit>83.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>95.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>60.40</ci_lower_limit>
            <ci_upper_limit>130.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP)</title>
        <description>Bone Specific Alkaline Phosphatase is a biomarker of bone formation and is measured in units of μg/L.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Per Protocol Population: defined as the subset of the APaT population that excluded participants based on critical protocol violations.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP)</title>
          <description>Bone Specific Alkaline Phosphatase is a biomarker of bone formation and is measured in units of μg/L.</description>
          <population>Per Protocol Population: defined as the subset of the APaT population that excluded participants based on critical protocol violations.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.51" lower_limit="20.23" upper_limit="39.51"/>
                    <measurement group_id="O2" value="50.04" lower_limit="39.60" upper_limit="61.25"/>
                    <measurement group_id="O3" value="49.98" lower_limit="39.08" upper_limit="61.73"/>
                    <measurement group_id="O4" value="51.64" lower_limit="40.42" upper_limit="63.76"/>
                    <measurement group_id="O5" value="-3.83" lower_limit="-10.41" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>53.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.31</ci_lower_limit>
            <ci_upper_limit>68.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>53.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.37</ci_lower_limit>
            <ci_upper_limit>66.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>55.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.19</ci_lower_limit>
            <ci_upper_limit>69.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>20.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.96</ci_lower_limit>
            <ci_upper_limit>35.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Mean Squares</param_type>
            <param_value>20.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.96</ci_lower_limit>
            <ci_upper_limit>35.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett's test at the primary time point of Month 12, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>22.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.47</ci_lower_limit>
            <ci_upper_limit>39.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Percent Change From Baseline to Month 12 in Serum Osteocalcin</title>
        <description>Serum osteocalcin is a biomarker of bone formation and is measured using units of nanograms (ng) / milliliter
(mL).</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Analysis of osteocalcin was not conducted when it was determined that the efficacy of MK-5442 was not significantly different than placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Percent Change From Baseline to Month 12 in Serum Osteocalcin</title>
          <description>Serum osteocalcin is a biomarker of bone formation and is measured using units of nanograms (ng) / milliliter
(mL).</description>
          <population>Analysis of osteocalcin was not conducted when it was determined that the efficacy of MK-5442 was not significantly different than placebo.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Trough Serum Calcium Level Exceeding Predefined Limits At Least Once</title>
        <description>Normal serum calcium level is 8-10 mg/dL (2-2.5 mmol/L) with some interlaboratory variation in the reference range, and hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL (&gt;2.5 mmol/L).
Based on these references, ≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with at least a one calcium level value ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; adverse event (AE). A Tier 1 AE was an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons.</description>
        <time_frame>Baseline through Month 12</time_frame>
        <population>All Participants as Treated (APaT): all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Participants were initially randomized to receive oral, once-daily MK-5442 15 mg and once-weekly matching placebo to alendronate for 12 months.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Trough Serum Calcium Level Exceeding Predefined Limits At Least Once</title>
          <description>Normal serum calcium level is 8-10 mg/dL (2-2.5 mmol/L) with some interlaboratory variation in the reference range, and hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL (&gt;2.5 mmol/L).
Based on these references, ≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with at least a one calcium level value ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; adverse event (AE). A Tier 1 AE was an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons.</description>
          <population>All Participants as Treated (APaT): all randomized participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥10.6 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥11.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥12.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Trough Albumin-Corrected Calcium Level Exceeding Predefined Limits At Least Once</title>
        <description>Albumin-Corrected Calcium = ([4 - plasma albumin in g/dL] × 0.8 + serum calcium).
≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with at least one albumin-corrected calcium level value ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; AE (an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons).</description>
        <time_frame>Baseline through Month 12</time_frame>
        <population>All Participants as Treated (APaT): all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Participants were initially randomized to receive oral, once-daily MK-5442 15 mg and once-weekly matching placebo to alendronate for 12 months.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Trough Albumin-Corrected Calcium Level Exceeding Predefined Limits At Least Once</title>
          <description>Albumin-Corrected Calcium = ([4 - plasma albumin in g/dL] × 0.8 + serum calcium).
≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with at least one albumin-corrected calcium level value ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; AE (an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons).</description>
          <population>All Participants as Treated (APaT): all randomized participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥10.6 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥11.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥12.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Predefined Tier 1 Adverse Events</title>
        <description>Osteonecrosis of the jaw (ONJ), kidney stones, and bone neoplasms were predefined Tier-1 AEs in the study (an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons).</description>
        <time_frame>Baseline through Month 12</time_frame>
        <population>All Participants as Treated (APaT): all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received oral matching placebo for MK-5442 or alendronate, based on their randomization to active drug or comparator arm.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 7.5 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Participants were randomized to receive oral, once-daily MK-5442 10 mg and once-weekly matching placebo to alendronate for 12 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Participants were initially randomized to receive oral, once-daily MK-5442 15 mg and once-weekly matching placebo to alendronate for 12 months.
The MK-5442 15-mg treatment arm was discontinued as a result of Amendment 1 and thus no outcome analyses were performed.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate 70 mg</title>
            <description>Participants were randomized to receive oral, once-weekly alendronate 70 mg plus once-daily matching placebo to MK-5442 for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Predefined Tier 1 Adverse Events</title>
          <description>Osteonecrosis of the jaw (ONJ), kidney stones, and bone neoplasms were predefined Tier-1 AEs in the study (an AE of special interest identified a priori that could be used for inferential testing for statistical significance for between-group comparisons).</description>
          <population>All Participants as Treated (APaT): all randomized participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Osteonecrosis of the jaw</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney stones</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All Participants as Treated (APaT); all randomized participants who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="E2">
          <title>MK-5442 5 mg</title>
          <description>Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="E3">
          <title>MK-5442 7.5 mg</title>
          <description>Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="E4">
          <title>MK-5442 10 mg</title>
          <description>Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="E5">
          <title>MK-5442 15 mg</title>
          <description>Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
        <group group_id="E6">
          <title>Alendronate 70 mg</title>
          <description>Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Coronary Heart Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hypertensive Heart Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Tako-Tsubo Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis Eosinophilic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Campylobacter Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Low Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Cancer of the Head of the Pancreas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Latigo Maligna Stage Unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Cerebral Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Migraine with Aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Anxiety Aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Thromboembolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E5" events="23" subjects_affected="23" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Knee Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>clincaltrialsdisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

